but it was last week when alkermese really got roaring again. the company announced some very positive clinical trial data for the same antidepressant that it previously failed to meet its targets. in response, the stock surged close to 30% in one day because this depression drug seems to be incredibly effective. i wouldn't be surprised if it's got more room to run. let's dig deeper with richard pops, the ceo of alkermese. mr. pops, welcome back to "mad money." good to see you. have a seat. how it happens, first a drug fails its primary end point. you very emphatically in the release said, listen, don't write us off. this could be good. and then it does work. what occurred in that period, and why is this drug different from the others? >> so first of all, doing clinical research in depression is incredibly difficult because when you enroll patients in a clinical trial for depression, many of the patients just get better by virtue of being in the trial itself. it's called the placebo effect. so when the study failed in january, we looked at the d

that's richard pops, chairman and ceo of alkermese, a guy who's doing the right thing. stick with cramer. "is that credit karma again?" "just wanna see if my score changed..you wanna check yours?" "scores don't change that much. i haven't changed." "oh really?" "it's girls'night. ah huh." "they said business casual." "i love summer weddings!" "oh no." "yeah, maybe it is time. maybe i should check my credit score." "try credit karma. it's free." "oh woah. that's different." ?when you've got...? ?...nausea, heartburn, indigestion, upset stomach, diarrhea!? ?nausea, heartburn, indigestion, upset stomach, diarrhea!? here's pepto bismol! ah. ?nausea, heartburn, indigestion, upset stomach, diarrhea!? mmm... i can't believe it's so delicious. i can't believe it has 40% fewer calories than butter. i can't believe it's made with real, simple ingredients. i can't believe we're on a whale. i can't believe my role isn't bigger. oh, it's real. real ingredients. unbelievable taste. >>> after the close, texas instruments reports a very, very good number. we had a caller earlier talk a

alkermese looks like it had some long-awaited success with its anti-depression drug, which could totally reinvent the company and give you a re-rated valuation beyond any specific examples, always remember that you need to stay flexible. if i can do it when all my opinions are caught on tape and i get raked over the coals every single time i change my mind, whether it be on here or for action alerts, my charitable trust, you can do it at home without anyone knowing it. when it comes to investing, a foolish consistency is the hobgoblin of little minds and bad stock pickers. so here's the bottom line. for investors, unlike politicians, flip-flopping is a virtue, not a vice. when the facts about a stock change, you've got to change your mind too. otherwise, you're likely to lose a lot of money and miss out on a ton of opportunities. let's go to james in new york. james. >> caller: booyah, jim. how are you? >> real good. how about you, james? >> caller: i'm doing fine, thank you. greetings from rochester, new york, the home of the protonix >> it is. fantastic. what's up? >> caller: i looked

alkermese. last night the drug company announced some very positive data on its break through antidepressant that works when other medications have failed and doesn't produce weight gain. this is the holy grail of one of the largest pharmaceutical markets out there. major props to richard pops, the ceo, for pressing forward relentlessly on this drug when others had given up on it. even up $12 or 28%, you know, i don't think the stock is done going higher although profit takers will no doubt swarm in eventually. but it wasn't all fair weather. my charitable trust may own nxpi semi and feeling good, but it also owns general electric. at ge, the orders were down 6% while the revenue disappointed. not disastrous, but certainly nothing to cheer about. i remain committed to it, but if the stock didn't have a decent yield, i bet it would go lower. three other disappointors worth mentioning. verizon, union pacific, and travelers. for verizon, blame more aggressive competitors like sprint and t-mobile. t